# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Subbu Nambi downgrades 10x Genomics (NASDAQ:TXG) from Buy to Neutral.
Jefferies analyst Tycho Peterson initiates coverage on 10x Genomics (NASDAQ:TXG) with a Hold rating and announces Price Targ...
New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed ...
Cathie Wood's flagship ARK Innovation ETF has been navigating through significant losses, showcasing the challenges faced b...